[1] WILLEM K, AMERY M D,PhD,FFPM. Signal Generation from Spontaneous Adverse Event Reports[J]. Pharmacoepidemiology and Drug Safety, 1999, 8: 147-150. [2] Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection[J]. Drug Saf, 2003, 26(3):159-186. [3] Bate A, Lindquist M, Edwards I R , et al, A Bayesian neural network method adverse drug reaction singal generation[J]. Eur J Clin Pharmacol, 1998, 54(4):315-321. [4] Clark J A, Klincewicz S L, Stang P E. Spontaneous adverse event signaling methods: classification and use with health care treatment products[J]. Epidemiol Rev, 2001, 23(2):191-210. [5] Egberts A C, Meyboom R H, van Puijenbroek E P. Use of measures of disproportionality in pharmacovigilance: three Dutch examples[J]. Drug Saf, 2002, 25(6):453-458. [6] Hauben M, Horn S, Reich L. Potential use of data-mining algorithms for the detection of‘surprise’ adverse drug reactions[J]. Drug Saf,2007, 30(2):143-155. [7] 魏水易,蒯丽萍,顾文华.贝叶斯法与可疑药物不良反应因果评价[J].药物不良反应杂志,2002,2:102-106. [8] van Puijenbroek E P, Bate A, Leufkens H G, et al, A comparison of measures of dispropor-tionality for signal detection in spontaneous reporting systems for adverse drug reactions[J]. Pharmacoepidemiol Drug Saf, 2002, 11(1):3-10. [9] Szarfman A, Machado SG, O’Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database[J]. Drug Saf, 2002, 25(6): 381-392. [10] Bate A, Lindquist M, Orre R. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs[J]. Eur J Clin Pharmacol, 2002, 58(7):483-490. [11] DuMouchel W. Bayesian data mining in large frequency tables, with application to FDA spontaneous reporting system[J]. Am Stat,1999,53(3): 177-190. [12] Emma L Heeley,Deborah Layton, Saad A Shakir. Signal generation in prescription event monitoring:investigation of a possible signal of colitis during rofecoxib treatment[J]. Inf Pharm Pract,2002,10(1):39. [13] P S Ang, E H Tan, K N Ting, et al. Analysis of ADR reports for year 2003[J]. Drug Safety, 2004:27(12):914-915. [14] de Vries T W, de Langen-Wouterse J J, van Puijenbroek E, et al, Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands[J]. Eur J Clin Pharmacol, 2006,62(5):343-346. [15] A K Salami, I A Katibi. Angiotensin converting enzyme-inhibitors associated cough: a prospective evaluation in hypertensives[J].Annals of African Medicine,2005,4(3):118-121. [16] Egberts A C, Meyboom R H, van Puijenbroek E P. Use of measures of disproportionality in pharmacovigilance:three Dutch examples[J]. Drug Saf, 2002; 25(6):453-458. [17] Van Puijenbroek E P, Egberts A C, Meyboom R H. Leufkens HG,Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole[J]. Br J Clin Pharmacol, 1999, 47(6):689-693. [18] 冉祟昭.日本最新药物不良反应报告[J].药学进展,1996,2:2-34. |